Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 266.97 Data as of May 17 |  +2.31 / +0.87%Today’s Change | 107.31 Today|||52-Week Range 283.99 | +56.06% Year-to-Date |
Latest REGN News | Press Releases
| Sanofi/REGN Commence Enrollment - Analyst Blog May 15 / Zacks.com | 3 Stocks Underperforming Today In The Drugs Industry May 15 / TheStreet.com |
| Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard May 15 / TheStreet.com |
Today’s Trading
| Previous close | 264.66 |
| Today’s open | 262.05 |
| Day’s range | 262.05 - 270.20 |
| Volume | 739,537 |
| Average volume (3 months) | 1,117,618 |
| Market cap | $26.2B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -41.06% |
| Earnings growth (next 5 years) | +34.36% |
| Revenue growth (last year) | +209.20% |
| P/E ratio | 35.5 |
| Price/Sales | 11.75 |
| Price/Book | 20.86 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CBSTCubist Pharmaceutica... | +0.88 | +1.81% |
| ARIAARIAD Pharmaceutical... | +0.20 | +1.21% |
| PRXLPAREXEL Internationa... | -0.12 | -0.26% |
| ISISIsis Pharmaceuticals... | +0.50 | +2.48% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | $0.85 |
| Annual revenue (last year) | $1.4B |
| Annual profit (last year) | $750.3M |
| Net profit margin | 54.43% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Leonard S. Schleifer, MD, PhD |
CFO, Treasurer & Senior VP-Administration Murray A. Goldberg, MBA |
Corporate headquarters Tarrytown, New York |
Forecasts
